Journal of Clinical Oncology (JCO) Podcast

Dr. Wiestner highlights characteristics of ibrutinib resistant CLL as reported by Woyach and colleagues and discusses how these data refine the management of CLL in the area of targeted therapy and can stratify patients for future clinical trials.

Summary and discussion of JCO paper by Yurgelun at al. using a 25-gene panel to demonstrate a nearly 10% germline mutation rate in colorectal cancer patients independent of high-risk factors.

By Stacie B. Dusetzina Considering the role of network coverage on access to accredited cancer institutions and potential out-of-pocket costs for patients. Related Article: Access to Accredited Cancer Hospitals Within Federal Exchange Plans Under the Affordable Care Act

By Linda E. Carlson This podcast discusses the target study in the context of other research on mindfulness-based interventions for cancer patients and survivors, providing a critique and suggestions for clinical interpretation and future research. Related Article: Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial

By Christopher R. Flowers Modeling studies like the one presented by Qiushi Chen and colleagues can project where needs and opportunities exist to address the pricing structure of medications and the selection of management strategies in CLL. Related Article: Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

This podcast provides commentary on a large dataset describing the expected frequency, severity and kinetics of immune-related adverse events associated with nivolumab monotherapy and the expected use of corticosteroid supportive therapy together with observations relating to the associations between immune adverse events, corticosteroid use and efficacy.

By Deepa Rangachari This podcast focuses on the use of trastuzumab in adjuvant therapy for early stage, Her2-positive breast cancer and ongoing efforts to identify predictive and prognostic biomarkers for the assessment of treatment-related cardiac toxicity. Related Article: Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy

If you are an oncologist and think that it isn't part of your job to listen to your patients talk about depression, I urge you to re-consider. As Sullivan and colleagues show, depression can be lethal.

This podcast highlights the innovative methodology employed in this study to determine risk factors for chemotherapy induced peripheral neuropathy, as well as implications of the findings to clinical practice and future investigation of immune mechanisms of this toxicity.

This podcast will assist readers in understanding the clinical implications of the paper by Yanik and colleagues. The paper describes the occurrence of Kaposi's sarcoma and lymphoma in the era of effective anti-HIV therapy where patients appear to be doing well from the standpoint of HIV clinical assessment, but continue to develop cancers associated with AIDS.

Implicit bias affects oncologists and their patients - a few steps can help

This podcast is a discussion of a clinical trial by Lesokhin et al which evaluated nivolumab monotherapy in patients with relapsed or refractory hematologic malignancies.

This podcast discusses the prevalence of and risk factors associated with a phenotype of accelerated aging among ALL survivors. Measurement and implications of frailty/pre-frailty are discussed.

This podcast comments on two independent pediatric studies on both sides of the Atlantic showing the relevance of 1q gain in poor prognosis Wilms tumors which raises the perspectives for therapeutic modifications.

While ten-year overall survival has increased for German patients with heritable retinoblastoma, treatment modalities including radiation and/or chemotherapy can impact overall survival.

The Children's Oncology Group study led by Larsen et al. showed that children and young adult patients with high-risk B cell acute lymphoblastic leukemia benefit from receiving high-dose methotrexate during interim maintenance 1 and that those aged 1 to 9 years benefit from receiving dexamethasone for 14 days during induction.

This podcast discusses the study by McMeekin and colleagues regarding their analysis of the prognostic and predictive implications of mismatch repair deficiency status among a tissue sample registry cohort of 1,024 endometrioid-type endometrial adenocarcinomas.

A central histopathological analysis of tumor material sampled within the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial shows that lymph node involvement is the only independent predictor of survival following chemotherapy plus resection

Restrictions on nutrition, social contacts, and pets are not effective anti-infective measures in children with acute myeloid leukemia.

This podcast will review results from screening ultrasound and tomosynthesis in women with dense breasts and will discuss current and future use of MRI screening which may include average risk women.

In this podcast, Dr. Andrew Ko discusses the SIRFLOX trial evaluating whether the addition of radioembolization to systemic chemotherapy confers any benefit in patients with liver-dominant metastatic colorectal cancer, and whether the results should compel us to rethink our use of this technology for this disease indication.

Impact of site of metastasis on overall survival in castration refractory prostate, and its implications on patient care and clinical trial design.

This podcast This JCO Podcast provides observations and commentary on the JCO article, "A European collaborative study of natural history, outcomes and validation of prognostic and response criteria in IgM related AL amyloidosis."

This podcast puts into context the findings from Hart and colleagues, highlighting the clinical care and research implications.

In this podcast, the article by Meropol et al. describing a randomized trial of a web-based educational tool versus a standard text-based resource is analyzed and placed in context of other challenges that limit the enrollment of adult cancer patients in contemporary clinical trials.

A study by Ramsey and colleagues suggests that extreme financial distress as manifested by personal bankruptcy might be associated with worse mortality in cancer patients. Long-term solutions have to focus on policy shifts involving how we set prices for drugs and how we design health insurance, but for more immediate solutions interventions have to focus on the oncologist and patient.

The Ki-67 proliferation index improves the prognostic value of the MIPI score.

An update on clinical trials that have included children with hepatocellular carcinoma

Ethnicity’s impact on diagnosis and survival of T-cell lymphoma

This podcast reviews the International Bladder Cancer Group’s recommendations regarding definitions and endpoints for the development of non-muscle-invasive bladder cancer clinical trials.

Discussion of a phase I trial of the checkpoint inhibitor atezolizumab in metastatic renal carcinoma.

This podcast reviews the accompanying article to provide the audience an understanding of the data and rationale to support updating the INRC primary site response criteria.

This podcast provides commentary on the importance of symptom assessment in Polycythemia Vera, and how this may impact therapeutic decision-making.

This podcast describes the evolving role of Gallium-68 somatostatin-receptor PET imaging in the evaluation of patients with well-differentiated neuroendocrine tumors, and compares the diagnostic sensitivity of this imaging modality to conventional scans.

Summarize the paper by Asselin et al and review the risks of therapy-related cardiomyopathy and evidence supporting dexrazoxane use in pediatric oncology.

Recent findings represent an important and exciting step in applying the rapid advance of sequencing technologies to generate molecularly-driven approaches towards the detection of gynecologic malignancies. More work is needed to better define and validate where such an approach might add most meaningfully in the search for effective methods of ovarian and endometrial cancer detection and diagnosis.

This podcast discusses the study by Hennink and colleagues regarding their randomized controlled trial of a 3-year versus 6-year interval for screening colonoscopies in individuals with a family history of colorectal cancer.

The randomized placebo controlled trial of progesterone receptor blockade showed no difference in survival, finally answering the question about hormonal therapy in this disease and raising new questions about how to move forward quickly.

This podcast reviews the current knowledge of staging and prognosis of mycosis fungoides and Sezary syndrome and evaluates the CLIC study, which aims to develop a prognostic index that can be used with patients who are diagnosed with advanced disease.

This podcast summarizes new evidence about the role of travel distance, oncologist density, and insurance in receipt of guideline-based chemotherapy for patients with stage III colon cancer.

This podcast will discuss the association of obesity and risk of developing colorectal cancer in Lynch syndrome patients based on a manuscript by Mohammad Movahedi and colleagues. In this manuscript, they report an association between obesity and increased risk of colorectal cancer as well as the potential benefit of aspirin to reduce the risk of colorectal cancer in obese Lynch syndrome patients.

Normal 0 false false false EN-US JA X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Cambria",serif; mso-ascii-font-family:Cambria; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Cambria; mso-hansi-theme-font:minor-latin;} Combined analysis of multiple phase three trials in multiple myeloma demonstrates improved outcomes with continued therapy